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Standfirst: Guidelines encourage the use of self-monitoring of blood pressure in 
pregnancy, and research suggests that women prefer it. But the blood pressure 
monitoring in pregnancy group (BUMP) explain that our enthusiasm may run ahead 
of the evidence. They outline what is known and call for better understanding before 
self-monitoring is implemented.  
 
Self-monitoring of blood pressure (BP) outside pregnancy is increasingly popular with 
patients and health care professionals. Around 1:3 people self-monitor
1
 and it is 
more accurate than BP readings taken in clinic.
2
 Anecdotal reports in the UK suggest 
that self-monitoring in pregnancy is commonplace, although few robust data exist to 
quantify this accurately.  
 
Around two thirds of women diagnosed with gestational hypertension were already 
self-monitoring according to a Canadian pilot survey.
3
 Another small, Canadian 
survey found that 78% of obstetricians used self-ŵoŶitoƌiŶg to ĐheĐk foƌ ͞white 
Đoat͟ hypeƌteŶsioŶ ;WCHͿ in women whom they diagnosed with hypertension in 
pregnancy, rather than ambulatory blood pressure measurement (ABPM; wearing a 
small digital blood pressure monitor that measures BP repeatedly over a 24-hour 
period).
4
 BP Guidelines recommend home monitoring for women with chronic 
hypertension and poorly controlled BP and for women with gestational 
hypertension, for example 2013 ACOG (American College of Obstetricians and 
Gynaecologists) guidelines, so it is likely that the practice will become more 
common.
5
 The American Heart Association (AHA)/ American Society of Hypertension 
(ASH)/ Preventive Cardiovascular Nurses Association (PCNA) joint statement
6
 and 
ESH guidelines have highlighted the importance and potential of self-monitored BP 
measurement and describe it as ͞theoƌetiĐally ideal foƌ ŵoŶitoƌiŶg changes in BP 
duƌiŶg pƌegŶaŶĐy͟.7  
 
If shown to be acceptable to women and accurate for screening and monitoring of 
normal and high BP in pregnancy, greater use of home monitoring could augment 
clinic based monitoring significantly. It may allow for the reorganisation of antenatal 
care. Availability of self-monitored results could allow health care professionals to 
spend more time on responding appropriately to BP results rather than actually 
performing monitoring. Alternatively, self-monitoring could integrate effectively with 
a group prenatal care model, wherein women do their own readings in the clinic and 
these are reviewed by the midwife.
8
  
 
There are reasons why self-monitoring may or may not be a good idea in pregnancy 
(see box 1). The aim of this article is to explain what is known about the evidence for 
self-monitoring and suggest a way forward. We extracted key studies from Medline 
searches up to March 2014, without limiting by publication date or language. We 
additionally searched the BHS
9
 and dabl
10
 websites (which both summarise BP 
monitor validation studies published in peer reviewed journals) to identify relevant 
validation studies. 
 
 
 
  
 
The scale of the problem  
Hypertensive disorders during pregnancy (box 2) are a leading cause of maternal 
mortality worldwide.
11
 They are associated with fetal growth restriction, low birth 
weight, preterm delivery, respiratory distress syndrome, and admission to neonatal 
intensive care.
12
  
 
In women who have died from pre-eclampsia, substandard care has been identified 
in 46% of maternal deaths and 65% of fetal deaths.
13
 In these cases, different 
management could reasonably have been expected to alter the outcome; in 
particular failures to identify and act on known risk factors at booking appointments 
and to recognise aŶd ƌespoŶd to sigŶs aŶd syŵptoŵs fƌoŵ 20 weeks’ gestatioŶ have 
been noted. This suggests that health care professionals could do better and may 
provide a basis for change from the status quo. 
 
One in ten women have raised BP (>140/90mmHg), with or without proteinuria, 
during pregnancy worldwide,
14
  and the proportion of women with high BP, and risk 
factors for high BP, is increasing. In the USA, for example, the percentage of women 
who are obese (BMI > 30) or overweight (BMI > 25) has increased almost 60% in the 
last 30 years - there is a three-fold increase in the risk of pre-eclampsia associated 
with obesity.
15,16
 The number of pregnant women over 40 in the UK has more than 
doubled in the last 24 years,
17
 and advanced maternal age is associated with around 
a 50% increase of pre-eclampsia.
18
 
 
Pre-eclampsia manifests long before clinical symptoms,
19,20
 and there is evidence 
that women in the UK develop the condition between antenatal visits. In 383 
confirmed cases of eclampsia, 323 (85%) women had been seen by a doctor or 
midwife in the week before their first convulsion, but at that point 36 (11%) had 
neither hypertension nor proteinuria, 32 (10%) had proteinuria but no hypertension, 
and 71 (22%) had hypertension alone.
21
   
 
Current guidelines recommend BP monitoring at routine antenatal visits with 
͞iŶĐƌeased fƌeƋueŶĐy͟ foƌ those at higheƌ ƌisk,22 but comprehensive systematic 
reviews have not identified any screening test (including those based on 
demographic characteristics, biomarkers or ultrasound screening) that have 
sufficient accuracy or cost-effectiveness to introduce into clinical practice, and 
consequently intermittent BP monitoring in a clinic setting remains the mainstay of 
pre-eclampsia detection in antenatal care.
23
 Earlier identification of rising BP 
amongst asymptomatic women could improve targeting of resources for close 
monitoring and outcomes. Such measurement provides a potential benefit of self-
monitoring between clinic appointments. 
 
Blood pressure in pregnancy  
Clinic measurements are more vulnerable to error compared to out-of-office 
monitoring; at home more measurements can be taken and white coat hypertension 
is avoided. The variability of BP is heightened in pregnancy,
24
 and debate continues 
  
about what constitutes normal blood pressure in pregnancy and how this may 
change by trimester. Clinic measurements could lead to unnecessary monitoring or 
missed opportunities to detect raised BP, though there are no reliable data to 
describe this currently. Data from ambulatory monitoring suggest that outcomes in 
those with white coat hypertension in pregnancy are similar to those with 
normotension.
25
 
 
Will women self-monitor? 
We know pregnant women are willing to undertake repeated self-measurements, 
comply with monitoring schedules
26
 and are able to accurately record BP data.
27
 It 
does not appear to increase anxiety,
28
 even when using more complex 
telemonitoring equipment.
29,30
 Clinicians promoting self-monitoring report being 
encouraged by woŵeŶ’s co-operation, competence and genuine desire to 
participate in their own healthcare.
Error! Bookmark not defined.31,32
 Over 98% of women with 
hypertension in pregnancy reported liking being involved in their BP management.
3 
 
 
Self-monitoring of BP in pregnancy is more acceptable to pregnant women than 
more frequent clinic visits,
33
 hospitalisation
30
 or ambulatory monitoring.
34,35
 In a 
study of 81 healthy pregnant women, 95% found self-monitoring of BP (using Omron 
HEM705CP) acceptable compared to 78% 24-hour ABPM.
36
 Home monitoring caused 
less discomfort, and rarely interfered with activities or disturbed sleep.  
 
Is self-monitoring accurate?   
There is a scarcity of home monitors validated and deemed accurate for use in 
pregnancy and in pre-eclampsia, in contrast to the number validated for use in the 
general population. Specific validation of monitors in a pregnant population is 
important because several monitors have in the past failed validation, mostly due to 
falsely low readings.
37,38
 Five monitors have been validated as being accurate within 
pre-defined margins by one of the three most widely used protocols produced by, 
respectively, the British Hypertension Society,
39
 the Association for the 
Advancement of Medical Instrumentation Standard,
40
 or the International Protocol 
of the European Society of Hypertension,
41
 for home use in pregnancy.
42,43,44,45,46
 
Even validated monitors may not be accurate for all pregnant women; for example, 
though obesity is an established risk factor for pre-eclampsia,
47
 when the accuracy of 
three commercially available devices was tested on 55 pregnant women with upper 
arm circumference >35cm, none was accurate.
48
  
 
How should self-monitoring be done? 
In essential hypertension, a minimum of three days and ideally seven days self-
monitoring is currently recommended, although the evidence underlying this is not 
particularly compelling.
49
 Conclusions from ambulatory monitoring in pregnancy 
suggest that a level of 135/85 mmHg best predicts future pregnancy-induced 
hypertension, but these threshold values have not been established firmly.
50,51
 Clear 
reference thresholds for self-monitoring have not been established to diagnose 
  
hypertension in pregnancy.
49,52
 Little data are available comparing clinic thresholds 
with self-monitored BP in pregnancy and the studies they are drawn from have 
significant methodological weaknesses. 
 
At a more basic level incomplete understanding of normal blood pressure in 
pregnancy means that any monitoring in pregnancy is challenging. BP changes 
through the trimesters, falling and then rising again, thus a woman may have a BP 
that starts at 100/70 mmHg, falls in mid-trimester to 90/60 mmHg and then rises to 
135/85 mmHg (for example), but is still considered within normal limits 
(<140/90mmHg by clinic measurement), despite the rise from booking BP. It is 
unclear whether monitoring frequency should change if there is a marked increment 
in blood pressure without crossing this threshold of 140/90 mmHg.
53
 Despite this, at 
present only the 140/90mmHg threshold is accepted for all trimesters.
26
 Women 
with pre-existing hypertension may have more unpredictable BP in pregnancy due to 
medication changes to stop treatment or change to safer medicines in early 
pregnancy. 
 
In the absence of clear evidence, there is little guidance on how often BP should be 
measured. The US guidelines recommend that in women with hypertension before 
pƌegŶaŶĐy ͞the diagŶosis should ďe ĐoŶfiƌŵed ďy ŵultiple ŵeasuƌeŵeŶts aŶd ŵay 
incorporate home or other out-of-offiĐe BP ƌeadiŶgs͟, ďut theƌe is Ŷo stateŵeŶt 
concerning what this means practically, for example how frequently BP should be 
measured.
 54
 NICE guidelines on hypertension in pregnancy conclude that research is 
needed to determine the optimal frequency and timing of measurement and on the 
role of screening for proteinuria in women who have existing hypertension and 
those who may develop pre-eclampsia.
55
  
 
Are pregnancy outcomes different if self-monitoring is used? 
It is not known whether self-monitoring will alter outcomes. In the UK, a pilot RCT 
included a weekly self-monitoring regime in eighty low risk women combined with a 
reduced antenatal visit schedule.
56
 A larger trial did not go ahead, perhaps because 
the predicted number of low risk women required was 10,000. A future trial may be 
better to focus on the role of self-monitoring in a higher risk group where fewer 
numbers would be needed and women would be more likely to gain benefit.
57
  
 
Few data exist on the safety of self-monitoring, but there are conflicting reports 
regarding how well women follow instructions from health care professionals.
33Error! 
Bookmark not defined.,58 
In one small study, women who recorded their own BP responded 
appropriately by contacting healthcare professionals when repeated readings were 
persistently raised.
59
 However, researchers found 10 out of 21 pregnant women in 
another study
42
  had poor understanding of the instructions given and the 
importance of alerting midwives in the Day Assessment Unit (DAU) when their BP 
was raised above a threshold. Issues included language barriers and personal/ work 
commitments.  
 
 
  
 
 
The bottom line 
Self-monitoring of BP appears to be feasible and acceptable to pregnant women. It 
might add to the efficacy of modern antenatal care. However, new evidence is 
required to establish the precise place of self-monitoring during and after pregnancy 
(see box 3). If self-monitoring is or becomes widespread, research may be difficult to 
undertake. We believe that until the evidence base is considerably stronger, further 
implementation of self-monitoring of BP in pregnancy, at least formally by the NHS, 
should be delayed. 
 
Regardless, the trend towards self-monitoring is set to increase, and it is important 
to acknowledge this and respect people's choices. We suggest that GPs and 
midwives at least need to be sensitive to this, and could enquire whether women in 
their care are self-monitoring, and if so would they like to share the results or 
receive any help interpreting them. They should also discuss the uncertainty around 
how the results are best interpreted. 
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Boxes 
  
Box 1:  
Advantages and disadvantages of home monitoring of blood pressure in 
pregnancy 
 
Potential advantages 
Increased accuracy 
Patient friendly 
Potential to free health care professional time or reduce clinic visits 
Potential to identify white coat hypertension  
 
Potential disadvantages 
Few monitors have been validated for use in pregnancy  
Poor understanding of normal blood pressure in pregnancy: no diagnostic 
thresholds for home monitoring of blood pressure in pregnancy   
No currently known blood pressure parameter in the early stage of pregnancy 
appears to permit reliable discrimination within white coat hypertensives between 
those who have continued white coat hypertension and those who develop either 
pre-eclampsia or gestational hypertension later in their pregnancy 
No evidence earlier detection of high blood pressure through home monitoring will 
alter outcomes 
No evidence on how to implement home monitoring in practice: optimal frequency 
and timing of home monitoring is unknown 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Box 2:  
Types of hypertension during pregnancy 
Chronic hypertension: hypertension (>140/90mmHg) present before 20 weeks or 
being treated at time of referral to maternity services 
Gestational hypertension: new hypertension presenting after 20 weeks without 
significant protoneuria 
Pre-eclampsia: new hypertension presenting after 20 weeks of pregnancy 
combined with significant proteinuria (if urinary protein: creatinine ratio > 
30mg/mmol or a validated 24hour urine collection results shows > 300mg protein)1 
White coat hypertension: hypertension (>140/90mmHg) at the clinic or office only, 
where ambulatory or home blood pressure is normal (typically using a threshold of 
<135/85 mmHg) 
 
  
  
Box 3:  
Research questions 
Can self-monitoring of BP lead to earlier detection of raised BP in pregnancy, and does 
this improve outcomes?  
What is the place of self-monitoring once raised BP has been detected?  
How does self-ŵoŶitoƌiŶg iŵpaĐt oŶ woŵeŶ’s kŶowledge aŶd ĐoŶfideŶĐe, theiƌ feeliŶgs 
about their body, their sense of self-efficacy and how they position themselves within 
care and in relation to professionals?  
Could self-monitoring help professionals to respond to more women-/ community-
centred approaches to care, thereby promoting partnership working? 
 
  
Table 1: Current monitors validated for home use in pregnancy 
   
 
Author 
(Year) 
Device Protocol Pregnancy Pre-
eclampsia 
Non-
proteinuric 
hypertension 
de Greeff 
(2006)43 
Microlife BP 
3AC1-1 
BHS A/A** 
 
B/A**  N/A 
  AAMI Pass** 
 
Pass** 
 
N/A 
Reinders 
et al 
(2005)44 
Microlife BP 
3BTO-A* 
BHS A/B A/B B/B 
  AAMI Pass Pass Pass 
Chung et 
al 
(2009)42  
Microlife 
WatchBP 
Home 
BHS A/A B/A 
 
N/A 
  AAMI Pass Pass 
 
N/A 
de Greeff 
et al 
(2009)45 
Omron M7 
(HEM-780-
E) 
BHS A/A B/B  N/A 
de Greeff 
et al 
(2009)45 
Omron MIT* 
 
BHS A/A A/A 
 
N/A 
Golara et 
al 
(2002)46 
Omron MIT* BHS B/A B/A 
 
N/A 
  AAMI Pass Pass 
 
N/A 
 
Notes: 
* These models are discontinued but equivalent monitors with slightly different model numbers 
though essentially similar hardware may be available. 
** This study has not been fully published (only as an abstract) and thus it is not possible to know 
if correct validation procedures were followed. 
 
BHS – British Hypertension Society protocol. Monitors can be rated from A to D, with A and B 
constituting a pass 
AAMI - Association for the Advancement of Medical Instrumentation protocol 
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